Annual Report from Cyxone AB for the period 1 January 2020 to 31 December 2020
Cyxone AB’s Annual Report for the financial year 2020 is now available at the company’s website (www.cyxone.com).
Please see attached Annual Report as pdf.Contact
Tara Heitner, CEO
Tel: +46 70 781 88 08
211 22 Malmö, Sweden
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, firstname.lastname@example.org. For more information, please visit www.cyxone.comOpen Annual Report